XTRA:E8X

Stock Analysis Report

Executive Summary

elexxion AG develops, produces, and sells dental lasers for soft and hard tissue applications primarily in Germany.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has elexxion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: E8X's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.8%

E8X

1.4%

DE Medical Equipment

-0.2%

DE Market


1 Year Return

-38.1%

E8X

25.0%

DE Medical Equipment

13.7%

DE Market

Return vs Industry: E8X underperformed the German Medical Equipment industry which returned 25% over the past year.

Return vs Market: E8X underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

E8XIndustryMarket
7 Day-1.8%1.4%-0.2%
30 Day-11.8%-3.3%0.3%
90 Day-6.3%1.4%3.7%
1 Year-38.1%-38.1%26.9%25.0%17.2%13.7%
3 Year-34.4%-34.4%144.1%137.7%15.4%5.3%
5 Year9.0%9.0%281.8%262.8%21.3%4.7%

Price Volatility Vs. Market

How volatile is elexxion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is elexxion undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether elexxion is trading at an attractive price based on the cash flow it is expected to produce in the future. But as elexxion has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of E8X’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through elexxion regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is elexxion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as elexxion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has elexxion performed over the past 5 years?

-6.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: E8X is currently unprofitable.

Growing Profit Margin: E8X is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: E8X is unprofitable, and losses have increased over the past 5 years at a rate of -6.7% per year.

Accelerating Growth: Unable to compare E8X's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: E8X is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17%).


Return on Equity

High ROE: E8X's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is elexxion's financial position?


Financial Position Analysis

Short Term Liabilities: E8X has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: E8X has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: E8X is debt free.

Reducing Debt: E8X's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: E8X has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if E8X's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if E8X has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if E8X has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is elexxion's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.4%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate E8X's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate E8X's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if E8X's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if E8X's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of E8X's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Xianlin Song (57yo)

0

Mr. Xianlin Song is Chairman of the Management Board of elexxion AG since November 2017. He is Chairman of the Management Board of Tian Ying Medical. He holds a Bachelor's degree in clinical medicine. 


Board Members

NamePositionTenureCompensationOwnership
Olaf Schäfer
Co-Founder and Member of Clinical Advisory Board0yrsno datano data
Oswald Gasser
Member of Supervisory Board9.6yrsno datano data
Rafael Navarro
Chairman of the Supervisory Board2.3yrsno datano data
Günter Paczkowski
Member of Supervisory Board2.3yrsno datano data

2.3yrs

Average Tenure

60yo

Average Age

Experienced Board: E8X's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Top Shareholders

Company Information

elexxion AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: elexxion AG
  • Ticker: E8X
  • Exchange: XTRA
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €3.246m
  • Shares outstanding: 9.90m
  • Website: https://www.elexxion.com

Number of Employees


Location

  • elexxion AG
  • Otto-Hahn-Strasse 7
  • Singen
  • Baden-Württemberg
  • 78224
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
E8XDB (Deutsche Boerse AG)YesBearer SharesDEEUROct 2006
E8XXTRA (XETRA Trading Platform)YesBearer SharesDEEUROct 2006

Biography

elexxion AG develops, produces, and sells dental lasers for soft and hard tissue applications primarily in Germany. It offers dental diode lasers under the elexxion pico, elexxion nano, and elexxion claros names; and elexxion pico lite, a soft laser therapy. The company also provides Odobleach, an in-office bleaching gel for treatment in a dental office; and perio green, a therapy product for the photothermal therapy of periodontology and periimplantitis, as well as offers repair services. It serves dental hygienists and assistants. The company was founded in 2002 and is headquartered in Singen, Germany. elexxion AG is a subsidiary of Tian Ying Medical Instrument Co., Ltd. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 21:24
End of Day Share Price2020/02/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.